Literature DB >> 32170351

[Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the German Hodgkin Study Group].

Bernd Frerker1, Guido Hildebrandt2.   

Abstract

Entities:  

Year:  2020        PMID： 32170351     DOI： 10.1007/s00066-020-01600-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  22 in total

1.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

Authors:  Andreas Engert; Annette Plütschow; Hans Theodor Eich; Andreas Lohri; Bernd Dörken; Peter Borchmann; Bernhard Berger; Richard Greil; Kay C Willborn; Martin Wilhelm; Jürgen Debus; Michael J Eble; Martin Sökler; Antony Ho; Andreas Rank; Arnold Ganser; Lorenz Trümper; Carsten Bokemeyer; Hartmut Kirchner; Jörg Schubert; Zdenek Král; Michael Fuchs; Hans-Konrad Müller-Hermelink; Rolf-Peter Müller; Volker Diehl
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

2.  Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials.

Authors:  Evert M Noordijk; Patrice Carde; Noëlle Dupouy; Anton Hagenbeek; Augustinus D G Krol; Johanna C Kluin-Nelemans; Umberto Tirelli; Mathieu Monconduit; José Thomas; Houchingue Eghbali; Berthe M P Aleman; Jacques Bosq; Marjeta Vovk; Tom A M Verschueren; Anne-Marie Pény; Théodore Girinsky; John M M Raemaekers; Michel Henry-Amar
Journal:  J Clin Oncol       Date:  2006-06-05       Impact factor: 44.544

3.  Chemotherapy alone for early Hodgkin's lymphoma: an emerging option.

Authors:  George P Canellos
Journal:  J Clin Oncol       Date:  2005-04-18       Impact factor: 44.544

4.  Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma.

Authors:  Ewa Bednaruk-Młyński; Joanna Pieńkowska; Adam Skórzak; Bogdan Małkowski; Waldemar Kulikowski; Edyta Subocz; Justyna Dzietczenia; Marta Zalewska; Krzysztof Leśniewski-Kmak; Renata Zaucha; Tomasz Wróbel; Jan M Zaucha
Journal:  Leuk Lymphoma       Date:  2014-06-27

5.  Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.

Authors:  Marc P E André; Théodore Girinsky; Massimo Federico; Oumédaly Reman; Catherine Fortpied; Manuel Gotti; Olivier Casasnovas; Pauline Brice; Richard van der Maazen; Alessandro Re; Véronique Edeline; Christophe Fermé; Gustaaf van Imhoff; Francesco Merli; Réda Bouabdallah; Catherine Sebban; Lena Specht; Aspasia Stamatoullas; Richard Delarue; Valeria Fiaccadori; Monica Bellei; Tiana Raveloarivahy; Annibale Versari; Martin Hutchings; Michel Meignan; John Raemaekers
Journal:  J Clin Oncol       Date:  2017-03-14       Impact factor: 44.544

6.  Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.

Authors:  James B Nachman; Richard Sposto; Philip Herzog; Gerald S Gilchrist; Suzanne L Wolden; John Thomson; Marshall E Kadin; Paul Pattengale; P Charlton Davis; Raymond J Hutchinson; Keith White
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

7.  Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?

Authors:  S Laskar; T Gupta; S Vimal; M A Muckaden; T K Saikia; S K Pai; K N Naresh; K A Dinshaw
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

8.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.

Authors:  Andreas Engert; Petra Schiller; Andreas Josting; Richard Herrmann; Peter Koch; Markus Sieber; Friederike Boissevain; Maike De Wit; Jorg Mezger; Eckhart Duhmke; Normann Willich; Rolf-Peter Muller; Bernhard F Schmidt; Helmut Renner; Hans Konrad Muller-Hermelink; Beate Pfistner; Jurgen Wolf; Dirk Hasenclever; Markus Loffler; Volker Diehl
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

9.  Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.

Authors:  Michael Fuchs; Helen Goergen; Carsten Kobe; Georg Kuhnert; Andreas Lohri; Richard Greil; Stephanie Sasse; Max S Topp; Erhardt Schäfer; Bernd Hertenstein; Martin Soekler; Martin Vogelhuber; Josée M Zijlstra; Ulrich Bernd Keller; Stefan W Krause; Martin Wilhelm; Georg Maschmeyer; Julia Thiemer; Ulrich Dührsen; Julia Meissner; Andreas Viardot; Hans Eich; Christian Baues; Volker Diehl; Andreas Rosenwald; Bastian von Tresckow; Markus Dietlein; Peter Borchmann; Andreas Engert
Journal:  J Clin Oncol       Date:  2019-09-10       Impact factor: 44.544

10.  Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Authors:  John Radford; Tim Illidge; Nicholas Counsell; Barry Hancock; Ruth Pettengell; Peter Johnson; Jennie Wimperis; Dominic Culligan; Bilyana Popova; Paul Smith; Andrew McMillan; Alison Brownell; Anton Kruger; Andrew Lister; Peter Hoskin; Michael O'Doherty; Sally Barrington
Journal:  N Engl J Med       Date:  2015-04-23       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.